1 |
Smyth EC, Nilsson M, Grabsch HI, et al. Gastric cancer [J]. Lancet, 2020, 396(10): 635-648.
|
2 |
Machlowska J, Baj J, Sitarz M, et al. Gastric cancer: epidemiology, risk factors, classification, genomic characteristics and treatment strategies [J]. Int J Mol Sci, 2020, 21(11): 4012.
|
3 |
Leja M, Linē A. Early detection of gastric cancer beyond endoscopy - new methods [J]. Best Pract Res Clin Gastroenterol, 2021, 50(4): 101731.
|
4 |
Gillen S. Advancing early gastric cancer detection [J]. FEBS Open Bio, 2021, 11(7): 1812-1813.
|
5 |
Douda L, Cyrany J, Tachecí I. Early gastric cancer [J]. Vnitr Lek, 2022, 68(6): 371-375.
|
6 |
Ortigão R, Libânio D, Dinis-Ribeiro M. The future of endoscopic resection for early gastric cancer [J]. J Surg Oncol, 2022, 125(7): 1110-1122.
|
7 |
Wu D, Zhang P, Ma J, et al. Serum biomarker panels for the diagnosis of gastric cancer [J]. Cancer Med, 2019, 8(4): 1576-1583.
|
8 |
Panarese A. Endoscopic resection for early gastric cancer: Towards a global understanding [J]. World J Gastroenterol, 2022, 28(13): 1377-1379.
|
9 |
Luo JJ, Wen FJ, Qiu D, et al. Nesfatin-1 in lipid metabolism and lipid-related diseases [J]. Clin Chim Acta, 2021, 522: 23-30.
|
10 |
Rupp SK, Stengel A. Interactions between nesfatin-1 and the autonomic nervous system-An overview [J]. Peptides, 2022, 149(3): 170719.
|
11 |
Kmiecik AM, Dzięgiel P, Podhorska-Okołów M. Nucleobindin-2/Nesfatin-1-A New Cancer Related Molecule [J]? Int J Mol Sci, 2021, 22(15): 8313.
|
12 |
Fan Z, Dong J, Mu Y, et al. Nesfatin-1 protects against diabetic cardiomyopathy in the streptozotocin-induced diabetic mouse model via the p38-MAPK pathway [J]. Bioengineered, 2022, 13(6): 14670-14681.
|
13 |
Wei Y, Li J, Wang H, et al. NUCB2/nesfatin-1: Expression and functions in the regulation of emotion and stress [J]. Prog Neuropsychopharmacol Biol Psychiatry, 2018, 81(2): 221-227.
|
14 |
Öztürk Özkan G. Effects of Nesfatin-1 on Food Intake and Hyperglycemia [J]. J Am Coll Nutr, 2020, 39(4): 345-351.
|
15 |
Dore R, Levata L, Lehnert H, et al. Nesfatin-1: functions and physiology of a novel regulatory peptide [J]. J Endocrinol, 2017, 232(1): R45-R65.
|
16 |
Kras K, Muszyński S, Tomaszewska E, et al. Minireview: Peripheral Nesfatin-1 in Regulation of the Gut Activity-15 Years since the discovery [J]. Animals (Basel), 2022, 12(1): 101.
|
17 |
Szeliga A, Podfigurna A, Meczekalski B. Nesfatin-1 as a potential marker for functional hypothalamic amenorrhea [J]. Gynecol Endocrinol, 2022, 38(11): 992-996.
|
18 |
Jiang S, Zhou W, Zhang X, et al. Developmental expression and distribution of nesfatin-1/NUCB2 in the canine digestive system[J]. Acta Histochem, 2016, 118(2): 90-96.
|
19 |
Pham V, Pemberton JG, Chang JP, et al. Nesfatin-1 stimulates the hypothalamus-pituitary-interrenal axis hormones in goldfish [J]. Am J Physiol Regul Integr Comp Physiol, 2021, 321(4): R603-R613.
|
20 |
Hui J, Aulakh GK, Unniappan S, et al. Localization of nucleobindin2/nesfatin-1-like immunoreactivity in human lungs and neutrophils [J]. Ann Anat, 2022, 239(1): 151774.
|
21 |
Tekin T, Cicek B, Konyaligil N. Regulatory peptide nesfatin-1 and its relationship with metabolic syndrome [J]. Eurasian J Med, 2019, 51(3): 280-284.
|
22 |
Wang XQ, Zheng Y, Fang PF, et al. Nesfatin-1 is a potential diagnostic biomarker for gastric cancer [J]. Oncol Lett, 2020, 19(2): 1577-1583.
|
23 |
Ren L, Bao D, Wang L, et al. Nucleobindin-2/nesfatin-1 enhances the cell proliferation, migration, invasion and epithelial-mesenchymal transition in gastric carcinoma [J]. J Cell Mol Med, 2022, 26(19): 4986-4994.
|
24 |
Zhang N, Li J, Wang H, et al. The level of Nesfatin-1 in a mouse gastric cancer model and its role in gastric cancer comorbid with depression [J]. Shanghai Arch Psychiatry, 2018, 30(2): 119-126.
|
25 |
Mohan H, Ramesh N, Mortazavi S, et al. Nutrients differentially regulate nucleobindin-2/nesfatin-1 in vitro in cultured stomach ghrelinoma (MGN3-1) cells and in vivo in male mice [J]. PLoS One, 2014, 9(12): e115102.
|